RSI Oversold Stocks
CMPX is flagged as RSI oversold, meaning recent selling pressure has pushed momentum to extreme levels that may lead to a short-term rebound.
COMPASS THERAPEUTICS INC (CMPX) Stock Price & Overview
NASDAQ:CMPX • US20454B1044
Current stock price
1.96 USD
+0.19 (+10.73%)
At close:
1.94 USD
-0.02 (-1.02%)
After Hours:
The current stock price of CMPX is 1.96 USD. Today CMPX is up by 10.73%. In the past month the price decreased by -64.04%. In the past year, price increased by 3.7%.
CMPX Key Statistics
52-Week Range1.61 - 6.88
Current CMPX stock price positioned within its 52-week range.
1-Month Range1.61 - 6.845
Current CMPX stock price positioned within its 1-month range.
- Market Cap
- 352.976M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.43
- Dividend Yield
- N/A
CMPX Stock Performance
Today
+10.73%
1 Week
-61.03%
1 Month
-64.04%
3 Months
-69.38%
Longer-term
6 Months -47.59%
1 Year +3.70%
2 Years +39.01%
3 Years -32.41%
5 Years N/A
10 Years N/A
CMPX Stock Chart
CMPX Stock Screens
CMPX currently appears in the following ChartMill screener lists.
CMPX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CMPX. When comparing the yearly performance of all stocks, CMPX is a bad performer in the overall market: 91.26% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
CMPX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CMPX. CMPX has a great financial health rating, but its profitability evaluates not so good.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CMPX Earnings
Next Earnings DateMay 13, 2026
Last Earnings DateMar 5, 2026
PeriodQ4 / 2025
EPS Reported-$0.09
Revenue Reported
EPS Surprise 2.39%
Revenue Surprise %
CMPX Forecast & Estimates
22 analysts have analysed CMPX and the average price target is 13.77 USD. This implies a price increase of 602.55% is expected in the next year compared to the current price of 1.96.
Analysts
Analysts87.27
Price Target13.77 (602.55%)
EPS Next Y4.9%
Revenue Next YearN/A
CMPX Index Membership
CMPX is currently included in the following stock indexes tracked on ChartMill.
CMPX Financial Highlights
Over the last trailing twelve months CMPX reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS decreased by -16.22% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-66.49M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.28% | ||
| ROE | -33.79% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%18.18%
Sales Q2Q%N/A
EPS 1Y (TTM)-16.22%
Revenue 1Y (TTM)-100%
CMPX Ownership
Ownership
Inst Owners79.19%
Shares180.09M
Float144.80M
Ins Owners6.82%
Short Float %18%
Short Ratio4.68
CMPX Industry Overview
CMPX operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
CMPX Latest News, Press Relases and Analysis
CMPX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CMPX
Company Profile
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2020-11-13. The firm is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Company Info
IPO: 2020-11-13
COMPASS THERAPEUTICS INC
80 Guest Street
Boston MASSACHUSETTS US
Employees: 39
Phone: 13026587581
COMPASS THERAPEUTICS INC / CMPX FAQ
What does CMPX do?
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2020-11-13. The firm is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Can you provide the latest stock price for COMPASS THERAPEUTICS INC?
The current stock price of CMPX is 1.96 USD. The price increased by 10.73% in the last trading session.
Does COMPASS THERAPEUTICS INC pay dividends?
CMPX does not pay a dividend.
What is the ChartMill rating of COMPASS THERAPEUTICS INC stock?
CMPX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the next earnings date for CMPX stock?
COMPASS THERAPEUTICS INC (CMPX) will report earnings on 2026-05-13.
Who owns COMPASS THERAPEUTICS INC?
You can find the ownership structure of COMPASS THERAPEUTICS INC (CMPX) on the Ownership tab.